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Adjuvant	chemotherapy	for	early	breast	cancer	patients	improves	survival	in	general,	
but	estimating	true	benefit	on	the	individual	level	remains	a	challenge,	especially	for	
older	individuals.	There	are	some	data	suggesting	that	older	individuals,	certainly	those	
at	higher	risk	of	relapse,	can	indeed	derive	benefit	from	adjuvant	chemotherapy,	and	
this	therapy	should	certainly	not	be	denied	on	the	basis	of	age	alone,	if	only	to	ensure	
equal	access	to	health	care1,	2.	There	are	many	studies	showing	provocatively	much	
lower	use	of	adjuvant	chemotherapy	in	older	people	probably	because	of	fear	for	
toxicity	and	futile	treatment1,	2,	but	also	very	likely,	although	poorly	reported,	because	
goals	in	life	shift	throughout	the	course	of	lifetime	from	mere	quantity	of	life	to	more	
quality	of	life.	Older	patients	more	often	die	from	other	causes	than	breast	cancer	and	
treatment	side	effects	can	seriously	affect	quality	of	life.		However	let	us	not	forget	that	
elderly	breast	cancer	patients	also	die	more	often	from	breast	cancer3,	demonstrating	
that	undertreatment,	the	other	extreme	position	mirroring	overtreatment,	can	
negatively	affect	outcome.		
	
If	the	decision	to	administer	adjuvant	chemotherapy	is	made	for	an	individual	old	
person,	the	next	question	is	the	choice	of	the	regimen.	Unfortunately	most	frequently	
used	regimens	have	been	studied	in	younger	fit	populations.	Some	studies	have	included	
a	proportion	of	patients	above	age	70,	but	actually	rather	a	selection	of	fitter	elderly,	not	
representative	of	the	general	population,	while	previous	studies4	have	even	debarred	
those	above	age	70	from	participation.	
	
There	are	many	reports	showing	higher	toxicity	with	standard	adjuvant	chemotherapy	
regimens	when	age	increases1,	2.	Hospitalisation	rate	is	also	clearly	higher	in	the	
elderly5.	In	the	adult	population,	the	classical	CMF	regimen	(cyclophosphamide,	
methotrexate,	fluorouracil)	has	largely	and	progressively	been	replaced	by	
anthracyclines‐based	regimens,	and	later	by	sequential	or	combined	anthracycline			and	
taxane	based	regimens,	because	of	improved	efficacy1.	However	the	use	of	
anthracyclines	remains	a	sensitive	matter	because	of	the	risk	of	cardiac	failure,	whose	
incidence	increases	with	age6.	Moreover	we	are	unaware	of	any	solid	evidence‐based	
validation	of	sequential	regimens	in	elderly,	even	when	avoiding	the	approved	”high	
dose”	of	docetaxel	(100	mg/m²)	or	the	triplet	TAC	(docetaxel,	doxorubicin,	
cyclophosphamide)	combination7,	both		highly	myelosuppressive,	especially	in	elderly	
for	whom	baseline	neutrophil	counts	are	often	misleading	to	estimate	bone	marrow	
functional	reserve.	For	all	these	reasons,	there	is	a	tendency	to	bypass	these	standard	
regimens	developed	in	younger	adults	when	treating	elderly	patients,	referring	to	
empirically	adjusted	ones	especially	in	those	patients	who	are	not	100%	fit	and	who	
represent	the	most	important	segment	of	the	elderly	population.	Few	attempts	have	
been	done	to	develop	elderly	specific	strategies.		
	
The	ELDA	trial	published	in	this	journal8	is	such	an	example.	The	study	randomized	302	
women	aged	65	to	79	years,	operated	for	breast	cancer,	with	average	to	high	risk	of	
recurrence,	to	CMF	or	weekly	docetaxel	for	4	to	6	cycles	according	to	hormone‐receptor	
status.	In	contrast	to	the	assumption,	docetaxel	did	not	improve	outcome	compared	with	
CMF	(HR	for	disease	free	survival	(DFS)	1,21;	p	0,32).	Haematological	toxicity	was	less	
pronounced	for	docetaxel,	but	non‐haematological	toxicity	and	quality	of	life	were	
conversely	significantly	worse:	of	note,	two	cases	of	intestinal	necrosis	events	yielding	
1.36%	toxic	death	rate	certainly	do	not	match	the	definition	of	“soft	chemotherapy”.	
However	the	authors	are	to	be	congratulated	for	performing	and	finishing	a	randomized	
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trial	in	the	older	population.	Several	trials	in	the	past	(CASA	trial,	ACTION	trial)	have	
failed	to	do	this,	supposedly	because	of	the	difficulty	to	convince	elderly	for	trial	
participation9	which	actually	may	be	an	emotional	interpretation	rather	a	fair	and	
objective	one.	Only	one	large	adjuvant	trial	in	this	population	has	been	published	
recently10,	showing	that	a	‘soft’	oral	adjuvant	chemotherapy	regimen	with	capecitabine	
is	clearly	inferior	to	standard	chemotherapy,	CMF	or	AC	(adriamycin,	
cyclophosphamide).	
	
How	should	we	interpret	the	results	of	the	ELDA	trial	in	this	context?	
First,	it	must	be	acknowledged	that	both	arms	(CMF	or	docetaxel	weekly)	are	not	
standard	adjuvant	regimens.	Weekly	docetaxel	has	not	been	previously	studied	as	
‘monotherapy’,	and	when	used	after	anthracyclines,	it	is	clearly	more	toxic	than	weekly	
paclitaxel	in	the	general	population11;	CMF	is	generally	considered	inferior	to	regimens	
combining	anthracyclines	and	taxanes,	as	mentioned	before.	Taken	together	with	the	
observed	toxicity	in	the	ELDA	trial,	this	does	not	encourage	the	use	of	either	regimen	in	
the	older	population	despite	the	lack	of	direct	comparisons	with	less	fuddy‐duddy	
regimens.	Because	of	this	poor	situation,	we	end	up	selecting	regimens	studied	in	the	
general	population	that	are	potentially	and	safely	usable	in	the	elderly.	Sequential	
regimens	like	AC	followed	by	weekly	paclitaxel	are	certainly	feasible,	but	only	in	fit	older	
patients,	not	forgetting	that	age	remains	a	clear	risk	factor	for	anthracycline‐related	
cardiotoxicity.	Although	attractive,	weekly	paclitaxel	monotherapy	in	the	general	(not	
high‐risk)	population12	did	not	achieve	non‐inferiority	compared	with	AC	(HR	for	RFS	
1.26),	so	cannot	be	recommended.	The	TC	(docetaxel	cyclophosphamide)	regimen13	is	
an	attractive	option	for	elderly	since	it	was	superior	to	AC	for	DFS	and	overall	survival	
(OS)	irrespective	of	age,	limiting	the	exposure	to	anthracyclines.	It	seems	feasible	in	the	
older	population13,	14	on	the	proviso	that	prophyactic	granulocyte‐colony	stimulating	
growth	factor	(G‐CSF)	is	used.	Liposomal	anthracyclines	also	have	the	potential	
advantage	of	reduced	cardiotoxicity	and	are	feasible	in	elderly15,	but	there	are	no	data	
on	efficacy	in	adjuvant	setting.	
	
A	second	issue	is	that	about	20%	of	the	ELDA	population	was	HER2‐positive,	and	only	
part	of	this	group	received	adjuvant	trastuzumab.	However	no	details	are	provided	in	
the	report	and	this	subgroup	is	too	small	in	any	case	to	allow	solid	conclusions.	Adjuvant	
chemotherapy	regimen	selection	in	HER2‐positive	disease	is	certainly	different	story.	
Like	in	HER2–negative	cases,	a	classical	sequential	chemotherapy	as	AC	followed	by	
weekly	paclitaxel,	combined	for	this	purpose	with	trastuzumab,	could	be	a	good	
treatment	choice	for	certain	patients.	But	the	use	of	two	independently	cardiotoxic	
drugs	may	put	patients	at	risk	of	additive,	if	not	synergistic,	cardiac	risk,	increasing	per	
se	according	to	age16.	That	the	adjuvant	trastuzumab	pivotal	trials	included	only	a	small	
amount	of	elderly	patients	unfortunately	nurtures	a	significant	or	ambiguous	grey	zone	
on	the	safety	of	such	combined	treatments.	The	TCH	(docetaxel,	carboplatin	
trastuzumab)	regimen	might	be	of	interest	specifically	for	elderly	since	it	does	not	
contain	anthracyclines	and	performs	more	or	less	similar	to	standard	anthracycline	and	
taxane	regimens	in	terms	of	outcome,	having	much	less	cardiac	toxicity4.	However	the	
study	which	assessed	its	value	had	an	upper	age	cut‐off	of	70	years,	so	there	are	no	data	
on	elderly	at	all.	Furthermore	the	high	dose	of	carboplatin	(AUC	6)	in	combination	with	
docetaxel	makes	this	schedule	very	unrealistic	for	the	majority	of	older	patients.	
Although	not	specifically	investigated	in	elderly,	there	are	recent	single	agent	phase	II	
data	using	an	anthracycline‐free	regimen	that	could	be	of	interest	for	older	patients	with	
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low‐	and	intermediate‐risk	of	relapse	or	who	present	with	comorbidities	that	could	
increase	cardiotoxicity.	In	an	open‐label	phase	II	study,	predominantly	in	node‐negative	
patients,	the	non‐anthracycline	TC	(docetaxel,	cyclophosphamide)	combination	with	
trastuzumab	was	effective	in	preventing	recurrence	of	breast	cancer	down	to	less	than	
3%	after	a	median	follow	up	of	3	years17.	More	recently,	data	have	been	orally	presented	
on	the	combination	of	weekly	paclitaxel	and	trastuzumab	in	node‐negative	HER2‐
positive	disease18.	As	in	the	former	study,	the	relapse	rate	was	encouragingly	low	(3‐
year	DFS	98.7%)	and	the	combination	seemed	well	tolerated,	although	taking	a	closer	
look	at	neurotoxicity	will	be	critical.	Thus	these	two	regimens	have	emerged	as	
acceptable	options	for	individual	cases	where	avoidance	of	anthracycline	related	
cardiotoxicity	is	important.	They	still	disagree	with	the	general	message	of	inferiority	of	
single	versus	combination	regimens,	and	as	such	deserve	further	scientific	validation.	
	
Last	but	not	least,	a	major	strength	of	the	ELDA	trial	is	the	inclusion	of	geriatric	
assessment	(GA).	This	has	hardly	been	integrated	in	clinical	trials	in	the	past.	It	provides	
crucial	information	about	the	general	health	status	of	included	patients19,	and	allows	
potentially	refined	analysis	for	identification	of	subgroups	that	will	benefit	more	or	less	
treatment.	In	the	ELDA	trial,	both	instrumental	activities	of	daily	living	(IADL)	and	
comorbidities	were	independently	associated	with	severe	non‐haematological	toxicity.	
GA	correlating	with	survival	and	treatment	toxicity,	it	could	therefore	contribute	to	a	
more	individualized	treatment	choice	in	older	individuals20,	as	advocated	by	the	
International	Society	of	Geriatric	Oncology	(SIOG)	in	its	10	priorities21.	
	
In	conclusion,	the	ELDA	trial	is	another	building	block	to	a	better	definition	of	adjuvant	
treatment	in	older	breast	cancer	patients.	Adapted	and	supposedly	so‐called	“soft”	
chemotherapy	regimens,	such	as	capecitabine	or	weekly	docetaxel	as	in	ELDA	trial,	are	
not	necessarily	better	than	old‐fashioned	although	standard	ones.	The	ELDA	study	does	
not	define	‘the’	new	standard	regimen	for	elderly.	More	importantly,	it	shows	how	
eagerly	awaited	future	research	in	this	domain	should	be	done,	such	as	the	ongoing	
ASTER	70s	phase	3	trial	(EudraCT	2011–004744‐22)	22	running	in	France	and	Belgium,	
in	order	to	improve	equity	and	solidarity	in	health	cares.	
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